Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Interest & Investment Income (2016 - 2026)

Perspective Therapeutics' Interest & Investment Income history spans 17 years, with the latest figure at $2.2 million for Q1 2026.

  • On a quarterly basis, Interest & Investment Income fell 7.84% to $2.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.9 million, a 32.18% decrease, with the full-year FY2025 number at $8.1 million, down 22.83% from a year prior.
  • Interest & Investment Income hit $2.2 million in Q1 2026 for Perspective Therapeutics, up from $1.6 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for CATX hit a ceiling of $3.6 million in Q3 2024 and a floor of $28000.0 in Q2 2022.
  • Historically, Interest & Investment Income has averaged $1.3 million across 5 years, with a median of $1.2 million in 2024.
  • Biggest five-year swings in Interest & Investment Income: crashed 88.95% in 2023 and later skyrocketed 4169.35% in 2024.
  • Tracing CATX's Interest & Investment Income over 5 years: stood at $561000.0 in 2022, then crashed by 88.95% to $62000.0 in 2023, then skyrocketed by 4169.35% to $2.6 million in 2024, then crashed by 39.03% to $1.6 million in 2025, then soared by 36.12% to $2.2 million in 2026.
  • Business Quant data shows Interest & Investment Income for CATX at $2.2 million in Q1 2026, $1.6 million in Q4 2025, and $2.0 million in Q3 2025.